- The Wall Street Journal•2 months ago
Specialty pharmaceutical company Savara Inc. said it would secure a New York Stock Exchange listing through a reverse merger with Mast Therapeutics Inc.
- Investopedia•2 months ago
Mast Therapeutics will merge with privately-held Savara Inc, which will be the surviving entity.
- PR Newswire•2 months ago
SAN DIEGO and AUSTIN, Texas, Jan. 7, 2017 /PRNewswire/ -- Mast Therapeutics, Inc. (Mast, NYSE MKT: MSTX) and Savara Inc. (Savara), a privately-held emerging specialty pharmaceutical company focused on the treatment of rare respiratory diseases, today announced that the two companies have entered into a definitive merger agreement, under which the stockholders of Savara would become the majority owners of Mast, and the operations of Mast and Savara would be combined.
YB4N.SG : Summary for Mast Therapeutics Inc. Register - Yahoo Finance
Mast Therapeutics Inc. Register (YB4N.SG)
Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
At close: 9:37PM CET
|Bid||0.00 x 1500000|
|Ask||0.00 x 1500000|
|Day's Range||0.11 - 0.11|
|52 Week Range||0.06 - 0.59|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|